Sitagliptin Utilization in Diabetic Patients with Coronary Artery Disease for Improving Cardiovascular Outcomes (SUPERIOR study)
- Conditions
- Coronary artery disease, Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000011894
- Lead Sponsor
- Department of Cardiovascular Medicine, Faculty of Life Sciences, Kumamoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1200
Not provided
1) Type 1 diabetes mellitus patients 2) Patients with severe diabetic ketosis, or nonketotic hyperosmolar coma within 6 months preceding enrollment 3) Patients needed treatment by DPP-4 inhibitors 4) Patients receiving GLP-1 receptor analogues injection 5) Patients needed treatment by glinide drugs 6) Patients with active systemic inflammatory disease, severe trauma, before and after the operation, and active hepatic disease 7) Unstable patients with Cerebral infarction, Cerebral hemorrhage, Subarachnoid hemorrhage, and transient ischemic attack within 1 month preceding enrollment 8) Patients with heart failure (New York Heart Association functional class III and IV, BNP more than 400pg/mL, or left ventricular ejection fraction <35%) 9) Patients planed coronary and peripheral artery revascularization 10) Patients with peripheral ischemic ulcer and gangrene 11) Patients treated by DPP-4 inhibitors at enrollment 12) Patients with pregnant, lactating, or planned or possible pregnant 13) Patients with a history of hypersensitivity to study drug 14) Ineligible patients for any other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method